List of Excipients in Branded Drug MIRALAX ORANGE FLAVOR

Generic Drugs Containing MIRALAX ORANGE FLAVOR

Company	Ingredient	NDC	Excipient
Bayer HealthCare LLC	polyethylene glycol 3350	11523-0122	SUCRALOSE

What are the Most Frequently-Used Excipients in MIRALAX ORANGE FLAVOR?

# Of NDCs	Excipient
1	SUCRALOSE

Miralax Orange Flavor Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

MiraLAX Orange Flavor is a polyethylene glycol 3350 powder for occasional constipation. Its commercial differentiation comes primarily from flavor, dissolution, dosing convenience, brand recognition, and retail distribution rather than active-ingredient exclusivity. The labeled excipient system uses citric acid, orange flavor, maltodextrin, potassium citrate, and sucralose to improve palatability and consumer acceptance while preserving a clear, drink-mix dosage form.[1]

The product has limited conventional patent protection. Generic and private-label polyethylene glycol 3350 products can compete on price, packaging, and channel access. The strongest commercial defenses are the MiraLAX trademark, consumer awareness, established retailer placement, formulation know-how, flavor quality, packaging execution, and regulatory familiarity.

What is the formulation of MiraLAX Orange Flavor?

MiraLAX Orange Flavor contains 17 grams of polyethylene glycol 3350 per adult dose. The labeled inactive ingredients are citric acid, flavor, maltodextrin, potassium citrate, and sucralose.[1]

Component	Function in the formulation	Commercial relevance
Polyethylene glycol 3350	Osmotic laxative active ingredient	Widely available and difficult to protect through composition patents alone
Citric acid	Acidulant and flavor modifier	Provides orange beverage acidity and supports flavor balance
Orange flavor	Consumer-facing taste system	Creates differentiation but may be replaceable by competitors
Maltodextrin	Carrier, bulking agent, and powder-processing aid	Supports uniform distribution of low-dose excipients and powder handling
Potassium citrate	Buffer and acidity modifier	Helps control taste and formulation performance
Sucralose	High-intensity sweetener	Reduces bitterness and improves acceptance without adding substantial sugar

The product is intended to be dissolved in 4 to 8 ounces of beverage and taken once daily by adults and children 17 years of age and older, subject to the label directions.[1]

How does the MiraLAX Orange Flavor excipient system work?

The formulation uses a low-moisture, water-dispersible powder rather than a ready-to-drink liquid. This reduces shipping weight, supports room-temperature storage, and allows the consumer to select the beverage used for administration.

Flavor and taste-masking strategy

Polyethylene glycol 3350 is generally considered relatively bland, but the complete powder system must still address the sensory effects of acidity, sweetener, and the large 17-gram dose. Orange flavor creates a recognizable consumer profile and helps make the product more acceptable when mixed with water or another beverage.

The excipient system appears designed around four sensory objectives:

1. Provide a recognizable citrus flavor.
2. Offset sourness from citric acid.
3. Maintain a low-calorie or sugar-free positioning through sucralose.
4. Avoid a thick, syrup-like mouthfeel associated with some liquid laxatives.

The key formulation risk is flavor performance after dilution. Orange flavor must remain identifiable across different beverage volumes and in both cold and room-temperature conditions. A replacement product that tastes strong in a concentrated sample but weak after dilution may perform poorly in consumer testing.

Buffering and beverage compatibility

Citric acid and potassium citrate create an acid-base system that can moderate acidity and stabilize the sensory profile. The system also affects compatibility with water, juice, sports drinks, coffee, and other permitted beverages.

A commercial reformulation would need to manage:

• Final pH after dilution.
• Flavor stability during shelf life.
• Interaction with minerals in hard water.
• Precipitation or haze.
• Sweetener aftertaste.
• Powder dissolution time.
• Residual grittiness.
• Moisture uptake during storage.

These attributes can be differentiated without changing the active ingredient. The opportunity is strongest in consumer experience rather than therapeutic effect.

What regulatory status does MiraLAX Orange Flavor have?

MiraLAX is an FDA-approved OTC polyethylene glycol 3350 product marketed for occasional constipation. The product is associated with NDA 022015 in the FDA Drugs@FDA database.[2]

The labeled use is short-term treatment of occasional constipation. The product label directs consumers to stop use and consult a physician if constipation continues after seven days or if certain warning symptoms occur.[1]

Regulatory issue	Status
Dosage form	Oral powder for solution
Active ingredient	Polyethylene glycol 3350
Labeled dose	17 grams once daily for adults and children 17 years and older
Therapeutic category	Osmotic laxative
FDA pathway	OTC product associated with NDA 022015
Pediatric positioning	Label provides directions for ages 17 and older; younger use requires physician direction
Prescription status	Marketed over the counter
Biosimilar pathway	Not applicable
FDA exclusivity	No current commercial exclusivity period is the primary barrier to competition

The product also sits within the broader FDA regulatory framework for OTC laxatives. FDA regulations identify polyethylene glycol 3350 as an osmotic laxative active ingredient under the laxative monograph framework.[3]

What is the Orange Book status of MiraLAX?

MiraLAX is linked to an FDA NDA, but its commercial protection is not comparable to a newly approved patented prescription drug. Publicly visible product protection is primarily associated with the brand and its market position rather than a substantial active patent estate.

The Orange Book is most relevant to approved prescription and certain NDA products that have listed patents or exclusivity. OTC competitors may also enter through applicable monograph or other FDA pathways without undertaking a conventional Paragraph IV challenge to a branded product patent.

No product-specific patent expiration date should be treated as the principal MiraLAX launch barrier. The practical entry question is whether a competitor can lawfully market a PEG 3350 product with compliant labeling, acceptable excipients, adequate manufacturing controls, and a commercially competitive package.

What patents protect MiraLAX Orange Flavor?

The primary protectable assets are likely to be non-patent rights and formulation know-how rather than a broad, enforceable patent monopoly over PEG 3350 orange powder.

Active-ingredient protection

Polyethylene glycol 3350 is an established polymeric laxative. The molecule and its basic osmotic use are not commercially protected by a new-drug patent estate comparable to a recently discovered small molecule.

A competitor can generally pursue a product containing PEG 3350 if it satisfies applicable FDA requirements and does not infringe any valid, enforceable formulation, manufacturing, packaging, or use patent.

Formulation patents

Potential formulation patent subjects could include:

• Specific particle-size distributions.
• Powder-flow characteristics.
• Moisture-control systems.
• Flavor encapsulation.
• Improved dissolution.
• Reduced grittiness.
• Sachet or unit-dose packaging.
• Stability of flavor components.
• Preservative-free dry powder systems.
• Combination products with electrolytes or additional active ingredients.

No such potential subject matter should be assumed to protect the marketed MiraLAX Orange Flavor product without a confirmed patent-family review. The public commercial strength of the product does not itself establish an enforceable formulation patent.

Trademark and trade dress

The MiraLAX name is a more important commercial asset than the PEG 3350 composition. Brand protection can cover the MIRALAX mark, related product names, and certain packaging elements. Trademark rights do not prevent a competitor from selling PEG 3350 orange-flavored powder under a different name, but they restrict confusingly similar branding and packaging.

When does MiraLAX lose exclusivity?

MiraLAX has already lost practical exclusivity over polyethylene glycol 3350. Competing PEG 3350 products, store brands, and generic-label products are available in the U.S. market.

The relevant timeline is therefore commercial rather than patent-driven:

Period	Market event
1990s to early 2000s	PEG 3350 products established as laxative products
2006	MiraLAX received FDA approval under NDA 022015.[2]
2000s onward	OTC PEG 3350 competition expanded across national brands and private labels
Current market	Competition centers on price, flavor, package size, retailer placement, and consumer trust

A new entrant does not need to wait for a future MiraLAX patent expiration date to compete with the product. The relevant barriers are FDA compliance, product quality, supply reliability, distribution, and marketing economics.

Do Paragraph IV challenges affect MiraLAX?

Paragraph IV litigation is unlikely to be the central entry mechanism for an orange-flavored OTC PEG 3350 competitor.

A Paragraph IV certification is an ANDA-based mechanism used to challenge listed patents associated with an approved drug application. A competitor seeking to sell an OTC PEG 3350 product under a monograph or other applicable regulatory route may not need to challenge a MiraLAX patent through the same process.

The principal legal questions are:

• Whether the competitor relies on an approved NDA, ANDA, or OTC monograph pathway.
• Whether any relevant MiraLAX patent is listed in the Orange Book.
• Whether the proposed formulation infringes a valid patent.
• Whether the competitor’s label falls within the permitted OTC use.
• Whether its branding or packaging creates trademark or trade-dress risk.

What generic entry risks exist for MiraLAX Orange Flavor?

Generic and private-label entry risk is high for the base product and moderate for the branded orange-flavor segment.

High-risk areas for the brand

Competitors can generally attack the product through:

• Lower-priced unflavored PEG 3350.
• Orange-flavored private-label products.
• Single-dose packets.
• Larger economy bottles.
• Retailer-exclusive products.
• E-commerce bundles.
• Products positioned as equivalent to MiraLAX.
• Subscription and direct-to-consumer sales.

The active ingredient is familiar to suppliers, and the excipient list is conventional. The technical barrier to producing a comparable powder is lower than the barrier for sterile injectables, biologics, modified-release systems, or complex inhalation products.

Remaining brand advantages

MiraLAX retains several advantages:

• High consumer recognition.
• Physician and pharmacist familiarity.
• Strong retail shelf presence.
• Simple once-daily dosing.
• Broad beverage-mixing flexibility.
• Established safety communication.
• National advertising and search visibility.
• Consumer trust in an FDA-approved labeled product.

The brand can defend share even when the product lacks strong patent protection. That defense is vulnerable when private-label products match the orange flavor, package design, dose clarity, and product claims.

What commercial opportunities exist in MiraLAX-like excipients?

The largest opportunities are adjacent dosage forms and improved consumer convenience.

Unit-dose stick packs

Single-dose sticks can reduce dosing errors and improve portability. A 17-gram packet provides a clear daily dose and supports travel, workplace, and subscription channels.

The main commercial issues are:

• Moisture-barrier packaging.
• Powder fill-weight control.
• Packet opening performance.
• Higher packaging cost.
• Increased packaging waste.
• Retail price premium.

Improved orange flavor systems

Flavor suppliers could develop differentiated citrus systems with:

• Lower sourness.
• Reduced sucralose aftertaste.
• Longer flavor persistence after dilution.
• Better performance in cold water.
• Lower dependence on artificial flavor declarations.
• Natural orange flavor positioning, subject to regulatory and labeling requirements.

Flavor improvement is commercially meaningful because consumers may use the product repeatedly over several days. A small sensory advantage can support private-label differentiation or a premium sub-brand.

Pediatric-oriented products

A lower-dose product or age-specific format could address parents seeking easier administration. This area carries higher regulatory and safety risk because the current MiraLAX label provides directions for ages 17 and older and directs younger use through physician consultation.[1]

Potential formats include:

• Physician-directed pediatric sachets.
• Smaller dose packets.
• Flavor systems designed for juice or milk.
• Premeasured dosing cups.
• Caregiver-oriented instructions.

Any pediatric positioning would require an appropriate regulatory and clinical basis. It should not be treated as a simple packaging extension.

Ready-to-drink and liquid formats

A ready-to-drink product could remove the need for consumer mixing, but it would introduce meaningful technical and economic burdens:

• Larger shipping volume.
• Microbial control.
• Preservative or aseptic-processing requirements.
• Flavor stability.
• Packaging cost.
• Greater carbon and logistics exposure.

The dry powder remains structurally advantaged for mass retail unless convenience commands a substantial price premium.

Sugar-free and clean-label positioning

Sucralose supports a sugar-free profile. A competitor could test stevia, monk fruit, or other sweetener systems, but those alternatives may create bitterness, lingering sweetness, or label complexity.

A clean-label product could remove or replace some excipients, but excipient reduction may impair taste, flow, or dose uniformity. The commercial opportunity is strongest when a replacement system improves consumer perception without increasing powder bulk or reducing stability.

How does MiraLAX compare with competing PEG 3350 products?

Criterion	MiraLAX Orange Flavor	Store-brand PEG 3350	Unflavored PEG 3350	Liquid laxative
Active ingredient	PEG 3350	Usually PEG 3350	PEG 3350	Varies
Flavor	Orange	Varies by retailer	Minimal or neutral	Often flavored
Dose form	Dry powder	Dry powder	Dry powder	Liquid
Dosing convenience	Consumer measures 17 grams	Similar	Similar	Premeasured or spooned
Patent barrier	Limited	Limited	Limited	Product-specific
Brand premium	High	Low to moderate	Low	Varies
Shipping efficiency	High	High	High	Lower
Key differentiation	Brand, flavor, trust	Price and retailer access	Price and flexibility	Ready-to-use convenience

MiraLAX is most exposed to private-label products that duplicate its dose, orange flavor, and package architecture. It is less exposed to unflavored products when consumers value taste, but unflavored products can win on price.

What manufacturing and IP barriers exist?

Manufacturing barriers are moderate but manageable. The product requires reliable blending, powder uniformity, moisture control, packaging integrity, and flavor consistency.

Key process controls include:

• Uniform distribution of sucralose and flavor.
• Consistent PEG 3350 particle characteristics.
• Prevention of agglomeration.
• Low moisture exposure.
• Accurate 17-gram dosing.
• Sachet seal integrity.
• Batch-to-batch sensory consistency.
• Stability testing under accelerated and long-term conditions.

The most defensible technical assets may be trade secrets covering flavor premixes, blending order, particle-size selection, moisture control, and packaging specifications. Those assets can support quality and reduce consumer complaints, but they do not prevent competitors from developing alternative processes.

Which companies are challenging MiraLAX commercially?

Competition comes from three groups:

1. National and regional OTC laxative brands.
2. Retailer-owned and store-brand PEG 3350 products.
3. E-commerce and contract-manufactured products.

The most effective challengers do not need to prove a superior clinical effect. They can compete through lower price, larger pack sizes, pharmacy recommendation, search placement, or equivalent-looking packaging.

Retailer private labels create the strongest structural pressure because they control shelf placement and can accept lower gross margins. Contract manufacturers also enable rapid launch of multiple flavors and package sizes.

What is the revenue exposure for MiraLAX?

Bayer does not generally disclose revenue for the MiraLAX Orange Flavor SKU separately. The commercial exposure is therefore best assessed through category structure rather than a product-level public revenue figure.

Revenue risks include:

• Private-label price compression.
• Retailer promotion and shelf replacement.
• Consumer migration to unflavored products.
• Store-brand orange-flavor matching.
• E-commerce discounting.
• Reduced brand advertising efficiency.
• Substitution by other laxative classes.

Revenue opportunities include:

• Premium single-dose sachets.
• Multipack and subscription formats.
• Improved flavor claims supported by testing.
• Retailer-exclusive variants.
• International localization of flavor and labeling.
• Healthcare-provider sampling.
• Bundles with hydration or digestive-health products.

Key Takeaways

• MiraLAX Orange Flavor uses PEG 3350 with citric acid, orange flavor, maltodextrin, potassium citrate, and sucralose.
• Its value proposition depends on palatability, simple mixing, brand recognition, and retail access.
• PEG 3350 has limited practical composition-based exclusivity.
• The product is associated with FDA NDA 022015 and is marketed OTC for occasional constipation.
• Orange Book and Paragraph IV issues are less important than monograph compliance, NDA strategy, trademark protection, and formulation noninfringement.
• Generic and private-label entry risk is high because the formulation is technically reproducible.
• The strongest opportunities are unit-dose sachets, improved flavor systems, premium packaging, and carefully regulated age-specific formats.
• Manufacturing know-how and flavor consistency can provide commercial advantage but are weaker barriers than patents.
• MiraLAX-specific revenue is not separately disclosed by Bayer.
• The most defensible assets are the brand, distribution, consumer trust, and sensory execution.

FAQs

Can a company sell an orange-flavored PEG 3350 product without licensing MiraLAX?

Yes, if the product satisfies the applicable FDA pathway and does not infringe valid patents, trademarks, or trade dress. A competitor cannot use MiraLAX branding or create confusingly similar packaging.

Is orange flavor itself patentable in a PEG 3350 laxative?

A generic orange flavor is unlikely to create meaningful patent protection. A specific encapsulated flavor system, stability profile, or manufacturing process could be patentable if it meets novelty, nonobviousness, and other legal requirements.

Could a private-label retailer duplicate the MiraLAX excipient list?

A retailer or contract manufacturer could develop a product using the same or similar inactive ingredients, subject to regulatory, quality, labeling, trademark, and patent constraints. Matching the list does not guarantee matching flavor or dissolution performance.

Does MiraLAX need a preservative?

The marketed dry powder formulation does not list a conventional antimicrobial preservative among its inactive ingredients.[1] A liquid version would face different microbial-control requirements.

Is PEG 3350 a biologic requiring biosimilar competition analysis?

No. PEG 3350 is a synthetic polymeric active ingredient, not a biologic. Competition is analyzed through OTC, NDA, ANDA, monograph, patent, trademark, and formulation considerations rather than the biosimilar pathway.

References

1. Bayer HealthCare Pharmaceuticals Inc. (n.d.). MiraLAX orange flavor polyethylene glycol 3350 powder for solution: Drug facts label. U.S. Food and Drug Administration, DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: MiraLAX, NDA 022015. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2023). 21 C.F.R. Part 346: Laxative drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-346

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. Bayer AG. (2024). Annual report 2023. https://www.bayer.com/en/investors/annual-reports and reports.